FDA Focusing On Ephedra Solution Within DSHEA Parameters, McClellan Says
This article was originally published in The Tan Sheet
Executive Summary
FDA is committed to operating within the confines of the Dietary Supplement Health & Education Act rather than seeking changes in the law as it prepares for action on ephedra-containing dietary supplements, according to FDA Commissioner Mark McClellan, MD/PhD
You may also be interested in...
Pedia Loss
Feb. 4 congressional letter to pediatric appetite suppressant marketer Dynamic Health Products marks expansion of House Energy & Commerce/Oversight & Investigations Subcommittee inquiry into dietary supplements aimed at children. Letter from Chairman James Greenwood (R-Penn.) follows previous correspondence. Greenwood notes the company previously said Pedia Loss is no longer publicly available, yet the product is still offered on the firm's 1website. Greenwood requests DHP provide records on development, marketing and any adverse events. The subcommittee previously targeted Skinny Pill for Kids. A separate investigation by the subcommittee into ephedra culminated in high-profile hearings which reignited the debate on the adequacy of protections under DSHEA (2"The Tan Sheet" July 28, 2003, p. 5)...
AERs Can Prove Causality – FDA Comments On GAO Ephedra Report
Statements that adverse event reports are not sufficient on their own to establish causality, "while technically true, are not an adequate reflection of current scientific standards for adverse event assessment," FDA states
Ephedra “Black Box” Warning Considered By FDA
FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C